Cherry Creek Investment Advisors Inc. Buys New Stake in Pfizer Inc. $PFE

Cherry Creek Investment Advisors Inc. purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, HoldingsChannel reports. The fund purchased 20,482 shares of the biopharmaceutical company’s stock, valued at approximately $510,000.

Other institutional investors have also bought and sold shares of the company. Peak Asset Management LLC increased its holdings in shares of Pfizer by 1.4% in the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after buying an additional 402 shares during the last quarter. Quest Investment Management LLC lifted its holdings in shares of Pfizer by 1.3% in the 3rd quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock valued at $809,000 after acquiring an additional 405 shares during the last quarter. Community Bank & Trust Waco Texas lifted its holdings in shares of Pfizer by 0.6% in the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after acquiring an additional 412 shares during the last quarter. CVA Family Office LLC grew its position in Pfizer by 3.3% in the third quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock worth $329,000 after acquiring an additional 413 shares in the last quarter. Finally, Boltwood Capital Management increased its stake in Pfizer by 0.7% during the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock worth $1,485,000 after acquiring an additional 420 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.1%

Shares of NYSE PFE opened at $28.08 on Wednesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $28.31. The firm has a 50-day simple moving average of $26.94 and a two-hundred day simple moving average of $25.75. The company has a market cap of $159.67 billion, a P/E ratio of 20.65 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter in the prior year, the firm posted $0.63 earnings per share. The company’s quarterly revenue was down 1.2% on a year-over-year basis. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Fresh real‑world data from Pfizer’s Swedish observational study on Ibrance (palbociclib) is being framed as a positive signal for the drug’s real‑world effectiveness and market durability, which could support oncology revenue expectations. Pfizer’s Swedish Ibrance Study
• Positive Sentiment: Heightened media and retail investor attention around Pfizer’s GLP‑1/weight‑loss pipeline (including coverage noting share strength despite a high‑profile “pass” comment) is boosting sentiment—investors are pricing potential upside from a once‑monthly treatment. Pfizer’s (PFE) Shares Up Since Jim Cramer Said “Pass”
• Positive Sentiment: Dividend appeal remains a tailwind for income investors—Pfizer is regularly cited among large caps with attractive dividends, supporting buy‑and‑hold interest. Pfizer – Among the 15 Large Cap Stocks with Highest Dividends
• Neutral Sentiment: Retail and institutional attention is elevated (high search/coverage), which can amplify moves but doesn’t guarantee direction — monitor whether flow sustains. Investors Heavily Search Pfizer Inc. (PFE)
• Neutral Sentiment: Broader sector moves (e.g., large deals and AI partnerships at peers) are reshaping investor rotation in healthcare but are not direct Pfizer catalysts; they do, however, affect relative valuation dynamics. Eli Lilly Ramps Up AI Ambitions
• Negative Sentiment: Fundamentals still carry risk: quarterly revenue was slightly down year‑over‑year even as EPS beat estimates, and Pfizer faces stiff competition in the GLP‑1/weight‑loss space from larger early movers—both could cap upside if execution or pricing weakens.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on PFE shares. Wolfe Research set a $24.00 price objective on Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. Barclays started coverage on Pfizer in a report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 target price for the company. Citigroup began coverage on Pfizer in a report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target on the stock. Guggenheim raised their price target on Pfizer from $35.00 to $36.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.19.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.